About this trial
This study will be done in two phases. Using stakeholder input (community advisory board (CAB)), the study team will adapt the SMART program to incorporate education and self-management support for use of Rescue Medication (RM) to manage seizure occurrence among Persons With Epilepsy (PWE) who have repetitive seizures. Additional content/support materials, pending input stakeholder might include posters/hand-outs that present information on the use of RM in a way that is engaging and salient to PWE. It is expected that participants will be in Phase 1 for about 3 months and participate in the CAB 2 or 3 times via zoom for 60-90 minutes/meeting. The advisory board will provide input on needed refinement of an adapted version of SMART based on their individual experiences. It is anticipate the total time commitment to be no more than 6 hours over 3 months, spread out over 2-3 meetings with review of materials possible in between meetings.
Phase 2: The investigators will use a 6-month prospective trial design to test engagement with and effects of SMART-RM among approximately 35 adult (≥ 18 years) PWE who have repetitive seizures.
Eligibility criteria
Qualifiers
Have epilepsy
Have experience with RM
Be 18 years or older
Be able to speak and understand English
Disqualifiers
Individuals who have had allergic reaction to diazepam or who have medical/psychiatric that are contraindications to the use of diazepam
Individuals prescribed opioid medications
Individuals with acute narrow angle glaucoma
Individuals with known dependence on benzodiazepines or current benzodiazepine abuse.
Trial design
Treatments tested in this trial
- SMART RM
- Valtoco Nasal Product